Trial Profile
Pilot study of atomoxetine to enhance COgnition in patients with schizophrenia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Oct 2017
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Cognition disorders; Schizophrenia
- Focus Therapeutic Use
- 16 Jul 2007 New trial record.